Is XOMAO or XRTX more undervalued in 2026?

CirclFi compares XOMA Royalty Corporation - Depo (XOMAO) and XORTX Therapeutics Inc. (XRTX) using 13 institutional-grade valuation models. XOMAO has a Quality of Company score of 8.2/10 while XRTX scores 3.4/10.

Which is a better buy — XOMAO or XRTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XOMAO and XRTX valuations compare?

XOMAO at $25.36 and XRTX at $2.26 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XOMAO vs XRTX Valuation Comparison 2026 — Intrinsic Value Analysis

XOMAO

Biotechnology

XOMA Royalty Corporation - Depo

Quality

8.2

out of 10

Value Trap

SAFE

Price

$25.36

Last close

Models

13/13

Active

XRTX

Biotechnology

XORTX Therapeutics Inc.

Quality

3.4

out of 10

Value Trap

—

Price

$2.26

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	XOMAO Fair Value	XOMAO Upside	XRTX Fair Value	XRTX Upside
Bayesian DCF	Intrinsic	$18.97	-25.0%	$4.91	+117.4%
Earnings Power Value	Intrinsic	$4.93	-80.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.30	-90.9%	$6.57	+190.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XOMAO vs XRTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XOMAO vs XRTX — Which Stock Is More Undervalued?

XOMAO scores higher with a 8.2/10 quality rating vs XRTX's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XOMA Royalty Corporation - Depo (XOMAO) and XORTX Therapeutics Inc. (XRTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XOMAO currently trades at $25.36 with a QOC of 8.2/10, while XRTX trades at $2.26 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).